NASDAQ:TNDM

Tandem Diabetes Care Stock News

etoro logo Buy TNDM
*Your capital is at risk
$18.03
-0.570 (-3.06%)
At Close: Jun 03, 2026
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The heavy selling pressure might have exhausted for Tandem Diabetes Care (TNDM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial
Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech.
Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pu
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock?
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - President
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.63 per share a year ago.
Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.
A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE